Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
Launched by NEUROMED IRCCS · Apr 25, 2022
Trial Information
Current as of August 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written informed consent;
- • PD diagnosis according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (UKPDS);
- • Age between 18 and 80 years (inclusive);
- • Hoehn \& Yahr staging \> 1;
- Exclusion Criteria:
- • Inability to provide written informed consent;
- • Diagnosis of other concomitant neurodegenerative disease;
- • Concomitant treatment with drugs similar to trehalose;
- • Hypersensitivity or intolerance to the active substance administered;
- • Severe swallowing problems;
- • Participation in other interventional studies within 30 days from the screening;
- • Other medical conditions that can interfere with results or endanger the participant.
About Neuromed Irccs
Neuromed IRCCS is a leading Italian research institute dedicated to advancing the field of neurology through innovative clinical trials and translational research. As a recognized center of excellence, Neuromed focuses on the prevention, diagnosis, and treatment of neurological disorders, leveraging cutting-edge methodologies and interdisciplinary collaboration. Committed to improving patient outcomes, the institute conducts rigorous clinical studies aimed at developing novel therapeutic strategies and enhancing understanding of complex neurological conditions. With a strong emphasis on scientific integrity and ethical standards, Neuromed IRCCS plays a pivotal role in shaping the future of neurology research and healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials